Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol

Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol

BackgroundBetween 30 and 50% of patients with major depressive disorder (MDD) do not respond sufficiently to antidepressant regimens. The conventional pharmacological treatments predominantly target serotonergic brain signaling but better tools to predict treatment response and identify relevant sub...

Full description

Bibliographic Details
Main Authors: Kristin Köhler-Forsberg, Anders Jorgensen, Vibeke H. Dam, Dea Siggaard Stenbæk, Patrick M. Fisher, Cheng-Teng Ip, Melanie Ganz, Henrik Enghusen Poulsen, Annamaria Giraldi, Brice Ozenne, Martin Balslev Jørgensen, Gitte Moos Knudsen, Vibe Gedsoe Frokjaer
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Psychiatry
Subjects:
major depressive disorder
biomarker
treatment response
serotonin 4 receptor
positron emission tomography
functional magnetic resonance imaging
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2020.00641/full

Internet

https://www.frontiersin.org/article/10.3389/fpsyt.2020.00641/full

Similar Items